Editor’s Highlight …… living with advanced prostate cancer is a mental burden – hear how our guys address it!
Long-term Xtandi use may suppresses PSA response; using Opdivo/nivolumab; addressing advanced PCa blues; ice cap (kap) for chemo & other tips; spot RT for oligo disease; dizziness when exercising; PSMA scans; how does AR V7 test direct treatment; using ultra sensitive PSA post RP; RADICALS-RT results; should you add 2nd line anti-androgen to chemo?
For a copy of the Chat URL’s and information, please go to our PCa Forum (click top right). And feel free to post there yourselves on any PCa related topic.
This interesting study coming from the renowned lab of Johann de Bono at the Institute for Cancer Research in the U.K. should help us understand why some patients may respond well to the promising PSMA-based therapeutics, like Lutetium 177-PSMA, and others may not.
Through analysis of prostate cancer samples, the authors report that the presence of prostate-specific membrane antigen (PSMA) is extremely variable both within one patient and between different patients. This may limit the usefulness of PSMA scans and PSMA-targeted therapies. They show for the first time that prostate cancers with defective DNA repair (e.g., BRCA, ATM mutations) produce more PSMA and so may respond better to PSMA-targeting treatments. The variability in PSMA production by prostate cancer cells was seen in both castrate sensitive and castrate resistant tumors.
